New Treatment for the Reduction of LDL: Inclisiran is an injectable small interfering RNA that targets the PCSK9 protein. In contrast to statins, it requires infrequent dosingand provides effective and sustained LDL-C reduction.
High levels of blood cholesterol, particularly low-density lipoproteins (LDL-C), are known to be a significant contributor to cardiovascular disease. In 2019, the FDA reviewed the application for inclisiran in treating primary hyperlipidemia in adults who have elevated LDL-C while on a maximally tolerated dose of statin therapy. Inclisiran is an injectable small interfering RNA that targets the PCSK9 protein. In contrast to statins, it requires infrequent dosing (twice per year) and provides effective and sustained LDL-C reduction in conjunction along with statins. Its prolonged effect may help alleviate medication non-compliance, one of the leading causes of failure to lower cholesterol levels. Inclisiran was FDA approved in December 2021 and is widely considered a game-changer for heart disease patients.
Latest from Today's Medical Developments
- The need for speed in high-speed machining
- FUCHS Lubricants’ NYEMED 7312
- Localizing robotics: Yaskawa's commitment to American manufacturing
- OPEN MIND Technologies’ hyperMILL 2025 CAM software innovations, enhancements
- July Lunch + Learn with SW North America
- Stryker raises full-year guidance despite muted investor reaction
- Unlocking 3D vision: Basler AG launches Stereo ace camera series
- Lisa Anderson, supply chain & manufacturing expert, comments on the One Big Beautiful Act and its implications for US manufacturers
